Cornell biomedical engineer James Antaki faced a setback when the Trump administration froze more than $1 billion in funding, forcing him to abandon his decade-long work on an artificial heart for babies. The funding freeze caused him to drain lab reserves, lay off staff, and nearly retire before grants were restored seven months later. Despite the return of funding, the damage to his research was already significant.

The pause disrupted development of a potentially life-saving device for approximately 14,000 children hospitalized with heart failure annually. With private industry largely uninterested in pediatric medical devices—only 0.6% of health technology seed funding targets such products—federal support represents the primary pathway for innovation in this niche market. The artificial heart would have addressed limitations of current options like the Berlin Heart, which has high complication rates.

Restoring funding couldn't rebuild lost momentum. Antaki's manufacturing partner walked away during the uncertainty, his postdoctoral student accepted another position, and university hiring freezes complicated rebuilding his team. The project suffered at least a 14-month setback—double the funding gap—while technical partnerships unraveled. The episode illustrates how research continuity, often undervalued in funding decisions, remains critical for medical innovation in specialized fields.